Clinical & regulatory strategy

From IND to BLA, with people who have filed both.

Protocol design, dose-escalation strategy, expedited pathways, and submission readiness — built by principals with 27 INDs, 9 NDAs, and 3 BLAs of direct filing experience, including a CD19 CAR-T.

Pre-IND and IND

Getting the filing right the first time

Pre-IND strategy, briefing packages, and CMC alignment with your manufacturing partners — coordinated early, not reconciled under a filing deadline. We also assess readiness for the proposed Expedited IND pathways under Operation TrialBlazer, where relevant to your program.

AyurDatta-ledCMC partner
First-in-human & dose optimization

Dose-escalation designs built for the modality

Bayesian and rule-based dose-escalation designs, clinically grounded DLT definitions, and dose-optimization strategy aligned with Project Optimus expectations — not a template pulled from a different modality's playbook.

AyurDatta-led
Protocol design

Physician-led, amendment-resistant protocols

Population, endpoints, and eligibility criteria written by a physician who has to defend them at a Type B meeting — not assembled from a boilerplate template. Optional ICH M11 structured-protocol authoring for programs standardizing ahead of the requirement.

AyurDatta-ledBiometrics partner (structured authoring)

Where this shows up

Roughly a quarter of clinical holds trace to avoidable CMC and quality gaps, and amendment-prone protocols are one of the three places sound science dies in Phase 2/3 — alongside population mismatch and enrollment infeasibility. Getting the protocol right the first time is the single highest-leverage document in the program.

Read our whitepaper on trial design →
Expedited pathways

Navigated, not just defined

Every expedited program comes with a real application and a real agency conversation behind it — not a glossary entry.

Fast Track & Breakthrough Therapy

Designation strategy built around the actual unmet-need and preliminary-evidence case your data supports.

RMAT

Regenerative Medicine Advanced Therapy designation for cell and gene therapy programs, including the alignment meetings it unlocks.

Accelerated Approval

Surrogate-endpoint strategy and the post-marketing confirmatory-trial commitments that come with it, planned from day one.

Real-Time Oncology Review (RTOR)

Iterative, rolling data submission ahead of a formal filing — coordinated so your data package is ready when the agency asks for it.

Project Orbis

Concurrent international review coordination across participating health authorities.

Orphan Drug & Rare Pediatric Disease

Designation applications and Priority Review Voucher strategy for rare-cancer and hematologic-malignancy programs.

Health authority interactions

Prepared for the meeting, not just the briefing book

Pre-IND, Type B, and Type C meeting preparation — briefing packages, anticipated-question rehearsal, and response strategy built by people who have sat on both sides of the table.

  • Briefing book authored to the question the agency will actually ask
  • Mock Q&A rehearsal before the real meeting
  • A response strategy ready before the minutes arrive
?

"We had the briefing book. We didn't have an answer for the question they actually asked."

The gap between a compliant briefing package and a meeting that goes your way.

NDA / BLA readiness

The submission holds up because it was built to

Red-team review

A comprehensive risk assessment of your submission before filing — gaps identified, questions anticipated, before the agency finds them first.

Integrated safety narrative

One coherent safety story across every module — not a patchwork assembled by whoever wrote each section.

Mock inspection

A rehearsal of the inspection question — with documentation gaps found and closed before an actual inspector asks.

AyurDatta-ledWriting partner (narrative authoring)
Breadth, without the boilerplate list

Solid tumor and hematologic malignancy depth, across the modalities that matter most

Our principals have led development programs spanning solid tumors and hematologic malignancies, with particular depth in the novel modalities where the regulatory and safety questions are hardest.

See expertise by modality →
How to start

Educate · Evaluate · Execute

Educate

Regulatory pathway briefing

Which expedited programs actually fit your data and timeline — for your board and your regulatory team.

Evaluate

IND or BLA red-team

A bounded, fixed-fee risk assessment of your submission — gaps, anticipated questions, and a remediation plan.

Execute

Protocol & signal definitions

Ongoing authorship and agency-interaction support, through submission and beyond.

See the full engagement path →

27 INDs · 9 NDAs · 3 BLAs

Book an IND or BLA red-team.

Bring us the submission, the pathway question, or the meeting you're preparing for.